List view / Grid view
28 April 2017 | By Niamh Marriott, Junior Editor
Results of the SARAH trial demonstrate that SIRT resulted in median overall survival (OS) of 8.0 months compared to 9.9 months with sorafenib (p=0.179)...
6 April 2017 | By Niamh Marriott, Junior Editor
BTG has received Class III CE Mark certification for DC Bead LUMI, the first commercially available radiopaque drug-eluting bead...
4 January 2017 | By Niamh Louise Marriott, Digital Editor
The application is based on data from the placebo-controlled Phase III trial which investigated the drug as a second line treatment...
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
RedHill Biopharma, will shortly commence a study evaluating yeliva (ABC294640) in patients with advanced hepatocellular carcinoma (HCC), pending final...
29 June 2016 | By Victoria White, Digital Content Producer
Results from the Phase III RESORCE trial investigating Bayer’s regorafenib in patients with unresectable hepatocellular carcinoma have been announced...
